Lacosamide Genepharm (Lacosamide)

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to reduce seizure activity.

• Partial‑onset seizures: provides adjunctive seizure control when monotherapy is insufficient.
• Primary generalized tonic‑clonic seizures: used as add‑on therapy to improve overall seizure management.
• Epilepsy syndromes requiring adjunctive treatment: helps achieve better seizure frequency reduction in refractory cases.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes hyperexcitable neuronal membranes and reduces the likelihood of repetitive firing. By selectively targeting the slow inactivation phase, it diminishes abnormal neuronal activity without markedly affecting normal conduction, contributing to its anticonvulsant effect.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Nausea: mild gastrointestinal upset.
• Headache: occasional tension‑type pain.
• Fatigue: feeling of reduced energy.
• Vision changes: blurred or double vision.
• Tremor: mild involuntary shaking.

Serious or Rare Side Effects

• Cardiac arrhythmia: PR‑interval prolongation requiring monitoring.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal thoughts: emergence of depressive symptoms.
• Hepatic dysfunction: elevated liver enzymes.
• Hypersensitivity: anaphylactic reactions.
• Respiratory depression: rare but potentially life‑threatening.

When prescribing Lacosamide, clinicians should consider several safety measures.

• Cardiac monitoring: assess ECG for PR‑interval changes, especially in patients with pre‑existing conduction disorders.
• Renal function: adjust use in severe impairment as drug clearance may be reduced.
• Hepatic function: evaluate liver enzymes; use caution in moderate to severe hepatic disease.
• Pregnancy: discuss potential risks with the patient; data are limited.
• Concomitant CNS depressants: monitor for additive sedation or respiratory effects.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Carbamazepine: may reduce lacosamide plasma levels, decreasing effectiveness.
• Phenytoin: can lower lacosamide concentrations, requiring close monitoring.

Moderate Interactions (Monitor Closely)

• CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide exposure.
• CYP2C19 inducers (e.g., rifampin): may decrease lacosamide levels.
• Other sodium channel blockers (e.g., lamotrigine): risk of additive cardiac conduction effects.
• CNS depressants (e.g., benzodiazepines): enhanced sedation or respiratory depression.
• Anticoagulants: monitor for potential changes in bleeding risk.